Call for Safer Stroke Prevention in A-Fib Patients Post-ICH
The ENRICH-AF trial results presented at the ESC Congress 2026 indicate that the drug edoxaban did not reduce stroke risk in patients with atrial fibrillation and a history of brain bleeds. Instead, the treatment was associated with an increase in major bleeding events, highlighting the need for safer alternatives.
Why it matters
This study addresses a critical clinical dilemma for aging populations, potentially changing how doctors manage stroke prevention in high-risk patients with complex medical histories.
The best approach to prevent strokes in high-risk patients with atrial fibrillation who have had an intracranial haemorrhage (brain bleed) remains uncertain.
The large ENRICH-AF trial compared oral anticoagulation with edoxaban vs. no anticoagulation.
Edoxaban did not reduce stroke or systemic embolism but increased major bleeding.
These findings support individualised decision-making and highlight the need for safer stroke-prevention strategies in this vulnerable population.
Munich, Germany - 29 August 2026: Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial fibrillation who had had an intracranial haemorrhage, according to results presented in a Hot Line session today at ESC Congress 2026. 1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in